Temporal aspects of heparin-induced thrombocytopenia

New England Journal of Medicine

Volumn 344, Issue 17, 2001, Pages 1286-1292

  Warkentin, T E ^a   Kelton, J G ^a  

^a HAMILTON REGIONAL LABORATORY MEDICINE PROGRAM   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; HEPARIN; SEROTONIN; THROMBOCYTE FACTOR 4;

ADULT; AGED; ARTICLE; BLEEDING; CONTROLLED STUDY; DRUG INDUCED DISEASE; FEMALE; HEPARINIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; SEROLOGY; SEROTONIN RELEASE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS; TIME;

AGED; ANTIBODIES; ANTICOAGULANTS; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; PLATELET COUNT; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA; TIME FACTORS;

EID: 0035953702     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200104263441704     Document Type: Article

References (33)

1. Arterial embolism occurring during systemic heparin therapy
2. Heparin induced thrombocytopenia with thrombotic and hemorrhagic manifestations
3. Heparin-induced immune thrombocytopenia
4. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin
5. Clinical picture of heparin-induced thrombocytopenia
6. 131) gene in patients with heparin-induced thrombocytopenia
7. 131 polymorphism, subclass-specific IgG anti-heparin/platelet factor 4 antibodies and clinical course in patients with heparin-induced thrombocytopenia and thrombosis
8. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia
9. Heparin-associated thrombocytopenia: Isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen
10. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells
11. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4
12. Antigens involved in heparin-induced thrombocytopenia
13. Heparin-induced thrombocytopenia: Laboratory studies
14. Heparin-induced thrombocytopenia: New evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation
15. Plasma P-selectin is increased in thrombotic consumptive platelet disorders
16. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia
17. Heparin-associated thrombocytopenia
18. Heparin-induced thrombocytopenia, thrombosis, and hemorrhage
19. Reexposure to heparin of patients with heparin-associated antibodies
20. A diagnostic test for heparin-induced thrombocytopenia
21. Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia
22. Laboratory testing for heparin-induced thrombocytopenia
23. Some non-parametric procedures
24. Nonparametric methods
25. Heparin-associated thrombocytopenia
26. Impact of the patient population on the risk for heparin-induced thrombocytopenia
27. Immunoreactions involving platelets. IV. Studies on the pathogenesis of thrombocytopenia in drug purpura using test doses of quinidine in sensitized individuals: Their implications in idiopathic thrombocytopenic purpura
28. Thrombocytopenia due to quinidine or quinine: Report on a series of 28 patients
29. Observations on cases of thrombocytopenic purpura due to quinine, sulphamezathine, and quinidine
30. Quinine-induced thrombocytopenia: A case report
31. Drug purpura due to surreptitious quinidine intake
32. Immunology of red cells
33. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia